Dual Immunomodulator Therapy With Adalimumab and Upadacitinib to Treat Recalcitrant Hidradenitis Suppurativa

Authors

Zahidul Islam, Albert Einstein College of Medicine
Solbie Choi, Albert Einstein College of Medicine
Lucy Wang, New York Medical College
Tyler M. Andriano, Albert Einstein College of Medicine
Kristina Campton, Albert Einstein College of Medicine

Author Type(s)

Student

Document Type

Article

Publication Date

2-1-2025

DOI

10.1016/j.jdcr.2024.12.008

Journal Title

Jaad Case Reports

Keywords

double-dose adalimumab, dual immunomodulator therapy, hidradenitis suppurativa, JAK and anti-TNF therapy, Janus kinase (JAK) inhibitors, refractory, TNF- α inhibitor, upadacitinib

Disciplines

Medicine and Health Sciences

Recommended Citation

Islam, Z., Choi, S., Wang, L., Andriano, T., & Campton, K. (2025). Dual Immunomodulator Therapy With Adalimumab and Upadacitinib to Treat Recalcitrant Hidradenitis Suppurativa. Jaad Case Reports, 56, 74-76. https://doi.org/10.1016/j.jdcr.2024.12.008